BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ponesimod readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ponesimod\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07362017-1919@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ponesimod: Phase 3 readout est. (NCT07362017)
DESCRIPTION:Ponesimod\, phase 3\, Psoriasis.\nStudy: Open Label Study to In
 vestigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chron
 ic Plaque Psoriasis\nEstimated primary completion: August 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ponesimod#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07362017
URL:https://assetmemo.bio/drug/ponesimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686081-1919@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Ponesimod: Phase 3 readout est. (NCT07686081)
DESCRIPTION:Ponesimod\, phase 3\, Ulcerative Colitis.\nStudy: Study to Eval
 uate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moder
 ately to Severely Active Ulcerative Colitis\nEstimated primary completion:
  April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ponesimo
 d#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 686081
URL:https://assetmemo.bio/drug/ponesimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
